SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
This Quarter Return
+19.42%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$1.87B
AUM Growth
+$1.87B
(-9.8%)
Cap. Flow
-$395M
Cap. Flow
% of AUM
-21.13%
Top 10 Holdings %
Top 10 Hldgs %
40.72%
Holding
114
New
19
Increased
26
Reduced
20
Closed
11
Top Buys
| 1 |
Las Vegas Sands
LVS
|
$39.7M |
| 2 |
NVIDIA
NVDA
|
$32.8M |
| 3 |
Global Payments
GPN
|
$27.7M |
| 4 |
RH
RH
|
$27.4M |
| 5 |
TSMC
TSM
|
$23.9M |
Top Sells
| 1 |
UnitedHealth
UNH
|
$73.2M |
| 2 |
Elevance Health
ELV
|
$67.7M |
| 3 |
Constellation Energy
CEG
|
$56.8M |
| 4 |
Estee Lauder
EL
|
$56.4M |
| 5 |
Colgate-Palmolive
CL
|
$54.4M |
Sector Composition
| 1 | Healthcare | 61.36% |
| 2 | Technology | 11.67% |
| 3 | Consumer Discretionary | 8.46% |
| 4 | Communication Services | 5.69% |
| 5 | Financials | 4.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MREO
51
Mereo BioPharma
MREO
$272M
| $9.72M | 0.52% | 7,364,438 | – | – |
|
52
Evercore
EVR
$12.4B
| $8.78M | 0.47% | +71,051 | New | +$8.78M |
|
53
Arcutis Biotherapeutics
ARQT
$1.86B
| $8.31M | 0.44% | 872,427 +193,036 | +28% | +$1.84M |
|
54
Alvotech
ALVO
$2.51B
| $7.74M | 0.41% | 1,000,000 | – | – |
|
|
55
Constellation Energy
CEG
$96.2B
| $7.56M | 0.4% | 82,592 -620,017 | -88% | -$56.8M |
|
56
Sanofi
SNY
$121B
| $6.25M | 0.33% | 116,041 +93,431 | +413% | +$5.04M |
|
|
57
UnitedHealth
UNH
$281B
| $6.16M | 0.33% | 12,823 -152,341 | -92% | -$73.2M |
|
58
BioNTech
BNTX
$24B
| $4.42M | 0.24% | 40,970 | – | – |
|
59
Elanco Animal Health
ELAN
$9.12B
| $4.4M | 0.24% | 436,900 | – | – |
|
60
PepGen
PEPG
$38M
| $4.35M | 0.23% | 486,611 -341,476 | -41% | -$3.05M |
|
|
AKLI
61
DELISTED
Akili, Inc. Common Stock
AKLI
| $4.26M | 0.23% | 3,841,718 | – | – |
|
62
Danaher
DHR
$147B
| $3.94M | 0.21% | 16,427 +5,300 | +48% | +$1.27M |
|
63
GFL Environmental
GFL
$18.2B
| $3.86M | 0.21% | +99,375 | New | +$3.86M |
|
64
Oric Pharmaceuticals
ORIC
$994M
| $3.83M | 0.2% | 492,924 -1,409,719 | -74% | -$10.9M |
|
65
Thermo Fisher Scientific
TMO
$186B
| $3.79M | 0.2% | 7,260 +2,200 | +43% | +$1.15M |
|
66
Benitec Biopharma
BNTC
$348M
| $3.12M | 0.17% | 769,000 | – | – |
|
67
Nurix Therapeutics
NRIX
$714M
| $2.8M | 0.15% | +280,760 | New | +$2.8M |
|
68
AstraZeneca
AZN
$248B
| $2.57M | 0.14% | 35,890 | – | – |
|
69
Natera
NTRA
$23.1B
| $2.53M | 0.14% | 51,900 | – | – |
|
|
MOLN
70
Molecular Partners
MOLN
$140M
| $2.49M | 0.13% | 400,000 | – | – |
|
71
Cencora
COR
$56.5B
| $2.4M | 0.13% | 12,488 -98,970 | -89% | -$19M |
|
72
Incyte
INCY
$16.5B
| $2.34M | 0.13% | 37,600 | – | – |
|
73
Abbott
ABT
$231B
| $2.25M | 0.12% | 20,620 | – | – |
|
74
Protagonist Therapeutics
PTGX
$3.67B
| $2.24M | 0.12% | +81,143 | New | +$2.24M |
|
75
Galapagos
GLPG
$2.07B
| $1.92M | 0.1% | 47,200 | – | – |
|